Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

@article{Fransson2014IntranasalDO,
  title={Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.},
  author={Moa E Fransson and Elena Piras and Hao Wang and Joachim Burman and Ida Rasmusson Duprez and Robert A. Harris and Katarina Leblanc and Peetra U Magnusson and Eva B. Brittebo and Angelica Loskog},
  journal={Immunology},
  year={2014},
  volume={142 3},
  pages={431-41}
}
Treatment with mesenchymal stromal cells (MSCs) is currently of interest for a number of diseases including multiple sclerosis. MSCs are known to target inflamed tissues, but in a therapeutic setting their systemic administration will lead to few cells reaching the brain. We hypothesized that MSCs may target the brain upon intranasal administration and persist in central nervous system (CNS) tissue if expressing a CNS-targeting receptor. To demonstrate proof of concept, MSCs were genetically… CONTINUE READING